{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:49:55Z","timestamp":1792698595073,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106690","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T08:44:54Z","timestamp":1755506694000},"page":"106690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0463-3495","authenticated-orcid":false,"given":"Judicaelle","family":"Didierjean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lanotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Courtois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germain","family":"Carr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"De Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vin","family":"Bigaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106690_bib0001","article-title":"Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations","volume":"12","author":"Ayzenberg","year":"2016","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.msard.2025.106690_bib0002","doi-asserted-by":"crossref","DOI":"10.1097\/WCO.0000000000000921","article-title":"Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients","volume":"34","author":"Calabrese","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106690_bib0003","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106690_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2025.106690_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106690_bib0007","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106690_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106690_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104803","article-title":"Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries","volume":"76","author":"Hrnciarova","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106690_bib0010","unstructured":"Johns Hopkins University. A pragmatic trial to evaluate the intermediate-term effects of early, Aggressive Versus Escalation Therapy in People With Multiple Sclerosis. Available from https:\/\/clinicaltrials.gov\/study\/NCT03500328. Accessed 25 July 2023."},{"key":"10.1016\/j.msard.2025.106690_bib0011","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1177\/1352458516675039","article-title":"Importance of early treatment initiation in the clinical course of multiple sclerosis","volume":"23","author":"Kavaliunas","year":"2017","journal-title":"Multiple Sclerosis J."},{"key":"10.1016\/j.msard.2025.106690_bib0012","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106690_bib0013","unstructured":"Medistica. pvalue.Io. 2019 pvalue.Io, a GUI of R statistical software for scientific medical publications. Available from https:\/\/www.pvalue.io Accessed 25 July 2023."},{"key":"10.1016\/j.msard.2025.106690_bib0014","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fnagi.2018.00238","article-title":"Interplay between age and neuroinflammation in multiple sclerosis: effects on motor and cognitive functions","volume":"10","author":"Musella","year":"2018","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.msard.2025.106690_bib0015","article-title":"A review in multiple sclerosis","volume":"82","author":"Ocrelizumab","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2025.106690_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106690_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106009","article-title":"Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol","volume":"95","author":"Ontaneda","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.msard.2025.106690_bib0018","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/NXI.0000000000001059","article-title":"Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis","volume":"8","author":"Prosperini","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinfl."},{"key":"10.1016\/j.msard.2025.106690_bib0019","first-page":"1212","article-title":"Association of No evidence of disease activity with no long-term disability progression in Multiple sclerosis: a systematic review and meta-analysis","volume":"10","author":"Rotstein","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106690_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/451912","article-title":"Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment","volume":"2015","author":"Shirani","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.msard.2025.106690_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106690_bib0022","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012726","article-title":"Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome","volume":"97","author":"Tintore","year":"2021","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:30:46Z","timestamp":1784345446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"alternative-id":["S2211034825004328"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106690","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106690"}}